{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:59:29Z","timestamp":1785517169722,"version":"3.56.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s43032-026-02136-1","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:44:20Z","timestamp":1781711060000},"page":"1199-1211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 Receptor Agonists in Reproductive Medicine: A Narrative Review and Investigational Pilot Survey of Patient Perspectives in Academic Reproductive Endocrinology"],"prefix":"10.1007","volume":"33","author":[{"given":"Alexander L","family":"Vlasak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palm","family":"Lindsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Minnihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Rhoton-Vlasak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"2136_CR1","unstructured":"World Health Organization. Obesity and overweight. 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight (accessed 1 2025)."},{"key":"2136_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s13669-023-00350-1","volume":"12","author":"A Nuako","year":"2023","unstructured":"Nuako A, Tu L, Reyes KJC, et al. Pharmacologic treatment of obesity in reproductive aged women. Curr Obstet Gynecol Rep. 2023;12:138\u201346.","journal-title":"Curr Obstet Gynecol Rep"},{"key":"2136_CR3","doi-asserted-by":"publisher","first-page":"e2695","DOI":"10.1210\/clinem\/dgaa285","volume":"105","author":"H Cena","year":"2020","unstructured":"Cena H, Chiovato L, Nappi RE, Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab. 2020;105:e2695\u20132709.","journal-title":"J Clin Endocrinol Metab"},{"key":"2136_CR4","doi-asserted-by":"publisher","unstructured":"King AA, Tan X, Dhopeshwarkar N et al. Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA. BMJ Open Diabetes Res Care. 2024;12. https:\/\/doi.org\/10.1136\/bmjdrc-2024-004431","DOI":"10.1136\/bmjdrc-2024-004431"},{"key":"2136_CR5","doi-asserted-by":"publisher","unstructured":"Li P, Varghese JS, Shah MK et al. 850-P: Trends in GLP-1RA use among individuals with type 2 diabetes (T2D) and\/or obesity\u2014insights from a nationwide electronic health record system, 2010\u20132023. Diabetes. 2024. https:\/\/doi.org\/10.2337\/db24-850-p","DOI":"10.2337\/db24-850-p"},{"key":"2136_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","volume":"184","author":"C Cesta","year":"2023","unstructured":"Cesta C, Rotem RS, Bateman B, et al. Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy. JAMA Intern Med. 2023;184:144\u201352.","journal-title":"JAMA Intern Med"},{"key":"2136_CR7","doi-asserted-by":"publisher","unstructured":"Muller DRP, Stenvers DJ, Malekzadeh A et al. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Front Endocrinol. 2023;14. https:\/\/doi.org\/10.3389\/fendo.2023.1215356","DOI":"10.3389\/fendo.2023.1215356"},{"key":"2136_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","volume":"33","author":"AM Chao","year":"2023","unstructured":"Chao AM, Tronieri JS, Amaro A, et al. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023;33:159\u201366.","journal-title":"Trends Cardiovasc Med"},{"key":"2136_CR9","doi-asserted-by":"publisher","first-page":"e083550","DOI":"10.1136\/bmjopen-2023-083550","volume":"14","author":"K Dao","year":"2024","unstructured":"Dao K, Shechtman S, Weber-Schoendorfer C, et al. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open. 2024;14:e083550.","journal-title":"BMJ Open"},{"key":"2136_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.5152\/jtgga.2015.15232","volume":"16","author":"Z\u00d6 Da\u011f","year":"2015","unstructured":"Da\u011f Z\u00d6, Dilbaz B. Impact of obesity on infertility in women. J Turk Ger Gynecol Assoc. 2015;16:111\u20137.","journal-title":"J Turk Ger Gynecol Assoc"},{"key":"2136_CR11","doi-asserted-by":"publisher","first-page":"e13145","DOI":"10.1111\/jne.13145","volume":"34","author":"TL Stincic","year":"2022","unstructured":"Stincic TL, Kelly MJ. Estrogenic regulation of reproduction and energy homeostasis by a triumvirate of hypothalamic arcuate neurons. J Neuroendocrinol. 2022;34:e13145.","journal-title":"J Neuroendocrinol"},{"key":"2136_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3390\/biomedicines12030653","volume":"12","author":"A Etrusco","year":"2024","unstructured":"Etrusco A, Miku\u0161 M, D\u2019Amato A, et al. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity and treatment with metformin and GLP-1s. Biomedicines. 2024;12:653.","journal-title":"Biomedicines"},{"key":"2136_CR13","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1007\/s40618-023-02084-6","volume":"46","author":"G Pugliese","year":"2023","unstructured":"Pugliese G, de Alteriis G, Muscogiuri G, et al. Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? J Endocrinol Invest. 2023;46:1761\u201374.","journal-title":"J Endocrinol Invest"},{"key":"2136_CR14","doi-asserted-by":"publisher","unstructured":"Bednarz K, Kowalczyk K, Cwynar M et al. The role of Glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome. Int J Mol Sci. 2022;23. https:\/\/doi.org\/10.3390\/ijms23084334","DOI":"10.3390\/ijms23084334"},{"key":"2136_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.rbmo.2017.03.023","volume":"35","author":"M Nylander","year":"2017","unstructured":"Nylander M, Fr\u00f8ssing S, Clausen HV, et al. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017;35:121\u20137.","journal-title":"Reprod Biomed Online"},{"key":"2136_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-18-0175","volume":"179","author":"V Salamun","year":"2018","unstructured":"Salamun V, Jensterle M, Janez A, et al. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018;179:1\u201311.","journal-title":"Eur J Endocrinol"},{"key":"2136_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12902-023-01500-5","volume":"23","author":"L Zhou","year":"2023","unstructured":"Zhou L, Qu H, Yang L, et al. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocr Disord. 2023;23:245.","journal-title":"BMC Endocr Disord"},{"key":"2136_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/AOG.0000000000005825","volume":"145","author":"J Finkle","year":"2025","unstructured":"Finkle J, Brost BC. Role of glucagon-like peptide-1 receptor agonists in people with infertility and pregnancy. Obstet Gynecol. 2025;145:286\u201396.","journal-title":"Obstet Gynecol"},{"key":"2136_CR19","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1080\/17512433.2021.1933433","volume":"14","author":"M Siamashvili","year":"2021","unstructured":"Siamashvili M, Davis SN. Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2021;14:1081\u20139.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2136_CR20","doi-asserted-by":"publisher","first-page":"1496416","DOI":"10.3389\/fphys.2024.1496416","volume":"15","author":"SS Du Plessis","year":"2024","unstructured":"Du Plessis SS, Omolaoye TS, Cardona Maya WD. Potential impact of GLP-1 receptor agonists on male fertility: a fable of caution. Front Physiol. 2024;15:1496416.","journal-title":"Front Physiol"},{"key":"2136_CR21","first-page":"50","volume":"60","author":"AA Varnum","year":"2023","unstructured":"Varnum AA, Pozzi E, Deebel NA, et al. Impact of GLP-1 agonists on male reproductive health-a narrative review. Med Kaunas Lith. 2023;60:50.","journal-title":"Med Kaunas Lith"},{"key":"2136_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s12020-023-03487-4","volume":"83","author":"M Liao","year":"2024","unstructured":"Liao M, Li X, Zhang H, et al. Effects and plasma proteomic analysis of GLP-1RA versus CPA\/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial. Endocrine. 2024;83:227\u201341.","journal-title":"Endocrine"},{"key":"2136_CR23","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/biolre\/ioad032","volume":"108","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Lin Y, Li G, et al. Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue. Biol Reprod. 2023;108:945\u201359.","journal-title":"Biol Reprod"},{"key":"2136_CR24","doi-asserted-by":"publisher","unstructured":"Jensterle M, Salamun V, Vrtacnik BE et al. Endometrial transcriptome alterations following short-term liraglutide treatment in infertile women with polycystic ovary syndrome and obesity. In: Endocrine Abstracts. Bioscientifica. 2024. https:\/\/doi.org\/10.1530\/endoabs.99.RC1.2","DOI":"10.1530\/endoabs.99.RC1.2"},{"issue":"4","key":"2136_CR25","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/humupd\/dmz019","volume":"25","author":"M Jensterle","year":"2019","unstructured":"Jensterle M, Jane\u017e A, Fliers E, et al. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Hum Reprod Update. 2019;25(4):504\u201317.","journal-title":"Hum Reprod Update"},{"key":"2136_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EC-18-0514","volume":"8","author":"M Jensterle","year":"2019","unstructured":"Jensterle M, Podbregar A, Goricar K, et al. Effects of liraglutide on obesity-associated functional hypogonadism in men. Endocr Connect. 2019;8:195\u2013202.","journal-title":"Endocr Connect"},{"key":"2136_CR27","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3390\/jcm12020672","volume":"12","author":"S La Vignera","year":"2023","unstructured":"La Vignera S, Condorelli RA, Calogero AE, et al. Sexual and reproductive outcomes in obese fertile men with functional hypogonadism after treatment with liraglutide: preliminary results. J Clin Med. 2023;12:672.","journal-title":"J Clin Med"},{"key":"2136_CR28","doi-asserted-by":"publisher","unstructured":"Salvio G, Ciarloni A, Ambo N et al. Effects of glucagon-like peptide 1 receptor agonists on testicular dysfunction: A systematic review and meta-analysis. Andrology. 2025. https:\/\/doi.org\/10.1111\/andr.70022","DOI":"10.1111\/andr.70022"},{"key":"2136_CR29","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3389\/fimmu.2018.01291","volume":"9","author":"V Garcia-Flores","year":"2018","unstructured":"Garcia-Flores V, Romero R, Miller D, et al. Inflammation-induced adverse pregnancy and neonatal outcomes can be improved by the immunomodulatory peptide exendin-4. Front Immunol. 2018;9:1291.","journal-title":"Front Immunol"},{"key":"2136_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2165\/00003088-199528030-00005","volume":"28","author":"GM Pacifici","year":"1995","unstructured":"Pacifici GM, Nottoli R. Placental transfer of drugs administered to the mother. Clin Pharmacokinet. 1995;28:235\u201369.","journal-title":"Clin Pharmacokinet"},{"key":"2136_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/MED.0000000000000835","volume":"30","author":"E Minis","year":"2023","unstructured":"Minis E, Stanford FC, Mahalingaiah S. Glucagon-like peptide-1 receptor agonists and safety in the preconception period. Curr Opin Endocrinol Diabetes Obes. 2023;30:273\u20139.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2136_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deae108.041","author":"K Hviid","year":"2024","unstructured":"HviidK, Banasik K, Mortensen LH, et al. P-779 GLP-1 receptor agonist treatment in early pregnancy and risk of pregnancy complications - A nationwide cohort study. Hum Reprod. 2024. https:\/\/doi.org\/10.1093\/humrep\/deae108.041","journal-title":"Hum Reprod"},{"key":"2136_CR33","unstructured":"The Faculty of Sexual and Reproductive Healthcare (FSRH). FSRH statement: Glucagon-like peptide-1 (GLP-1) agonists and oral contraception. The College of Sexual and Reproductive Healthcare. 2025. https:\/\/www.fsrh.org\/Public\/Public\/Documents\/FSRH-statement-Glucagon-like-peptide-1-agonists-and-oral-contraception-Feb-2025.aspx.\u00a0Accessed Feb 2025."},{"key":"2136_CR34","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1097\/AOG.0000000000004395","volume":"137","author":"Obesity in pregnancy","year":"2021","unstructured":"Obesity in pregnancy. ACOG Practice Bulletin, Number 230. Obstet Gynecol. 2021;137:e128\u201344.","journal-title":"Obstet Gynecol"},{"key":"2136_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ajog.2024.08.024","volume":"232","author":"RF Drummond","year":"2025","unstructured":"Drummond RF, Seif KE, Reece EA. Glucagon-like peptide-1 receptor agonist use in pregnancy: a review. Am J Obstet Gynecol. 2025;232:17\u201325.","journal-title":"Am J Obstet Gynecol"},{"key":"2136_CR36","unstructured":"Tirzepatide. (Mounjaro\u00ae, Zepbound\u00ae). In: MotherToBaby | Fact Sheets. Brentwood, TN: Organization of Teratology Information Specialists (OTIS). 1994. Accessed 1 June 2025. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK605070\/. Accessed 1 June 2025."},{"key":"2136_CR37","unstructured":"U.S. Food & Drug Administration. Mounjaro US, Prescribing information. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215866s000lbl.pdf (2022)."},{"key":"2136_CR38","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/jcph.443","volume":"55","author":"C Kapitza","year":"2015","unstructured":"Kapitza C, Nosek L, Jensen L, et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, Ethinylestradiol\/Levonorgestrel. J Clin Pharmacol. 2015;55:497\u2013504.","journal-title":"J Clin Pharmacol"},{"key":"2136_CR39","unstructured":"U.S. Food & Drug Administration. Ozempic US, Prescribing information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf"},{"key":"2136_CR40","doi-asserted-by":"publisher","first-page":"T1","DOI":"10.1530\/JOE-13-0414","volume":"221","author":"L van Bloemendaal","year":"2014","unstructured":"van Bloemendaal L, Ten Kulve JS, la Fleur SE, et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2014;221:T1\u201316.","journal-title":"J Endocrinol"},{"key":"2136_CR41","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/cen.13454","volume":"87","author":"X Liu","year":"2017","unstructured":"Liu X, Zhang Y, Zheng S-Y, et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight\/obese polycystic ovary syndrome. Clin Endocrinol (Oxf). 2017;87:767\u201374.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2136_CR42","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1210\/jc.2008-0115","volume":"93","author":"K Elkind-Hirsch","year":"2008","unstructured":"Elkind-Hirsch K, Marrioneaux O, Bhushan M, et al. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:2670\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"2136_CR43","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s00404-022-06700-3","volume":"306","author":"R Li","year":"2022","unstructured":"Li R, Mai T, Zheng S, et al. Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. Arch Gynecol Obstet. 2022;306:1711\u201321.","journal-title":"Arch Gynecol Obstet"},{"key":"2136_CR44","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12902-023-01497-x","volume":"23","author":"Y Hu","year":"2023","unstructured":"Hu Y, Song X, Hamiti S, et al. Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis. BMC Endocr Disord. 2023;23:250.","journal-title":"BMC Endocr Disord"},{"key":"2136_CR45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/bs.ircmb.2016.05.002","volume":"326","author":"R Sekar","year":"2016","unstructured":"Sekar R, Singh K, Arokiaraj AWR, et al. Pharmacological actions of glucagon-like peptide-1, gastric inhibitory polypeptide, and glucagon. Int Rev Cell Mol Biol. 2016;326:279\u2013341.","journal-title":"Int Rev Cell Mol Biol"},{"key":"2136_CR46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/dom.13053","volume":"20","author":"S Fr\u00f8ssing","year":"2018","unstructured":"Fr\u00f8ssing S, Nylander M, Chabanova E, et al. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. Diabetes Obes Metab. 2018;20:215\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"2136_CR47","first-page":"70","volume":"27","author":"M Ivani\u0161evi\u0107","year":"2018","unstructured":"Ivani\u0161evi\u0107 M, Herman M, Horvati\u010dek M, et al. Pregnancy outcome and liraglutide levels in serum and umbilical vein blood of a woman with type 2 diabetes. A case report. Gynaecol Perinatol J Gynaecol Perinatol Reprod Med Ultrason Diagn. 2018;27:70\u20132.","journal-title":"Gynaecol Perinatol J Gynaecol Perinatol Reprod Med Ultrason Diagn"},{"key":"2136_CR48","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1111\/dme.12726","volume":"32","author":"D Greco","year":"2015","unstructured":"Greco D. Normal pregnancy outcome after first-trimester exposure to liraglutide in a woman with type 2 diabetes. Diabet Med J Br Diabet Assoc. 2015;32:e29\u201330.","journal-title":"Diabet Med J Br Diabet Assoc"},{"key":"2136_CR49","doi-asserted-by":"publisher","first-page":"170624","DOI":"10.1016\/j.peptides.2021.170624","volume":"145","author":"L-M Wu","year":"2021","unstructured":"Wu L-M, Wang Y-X, Zhan Y, et al. Dulaglutide, a long-acting GLP-1 receptor agonist, can improve hyperandrogenemia and ovarian function in DHEA-induced PCOS rats. Peptides. 2021;145:170624.","journal-title":"Peptides"},{"key":"2136_CR50","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00592-022-01954-4","volume":"60","author":"S Burlina","year":"2023","unstructured":"Burlina S, Dalfr\u00e0 MG, Caprino R, et al. A case report on use of dulaglutide during the first weeks of pregnancy in woman affected by type 2 diabetes mellitus. Acta Diabetol. 2023;60:137\u20138.","journal-title":"Acta Diabetol"},{"key":"2136_CR51","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/jim-2021-001952","volume":"70","author":"G Singh","year":"2022","unstructured":"Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022;70:5\u201313.","journal-title":"J Investig Med"},{"key":"2136_CR52","unstructured":"U.S. Food & Drug Administration. Wegovy US Prescribing, Information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215256s007lbl.pdf"},{"key":"2136_CR53","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12958-024-01339-y","volume":"23","author":"J Duah","year":"2025","unstructured":"Duah J, Seifer DB. Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review. Reprod Biol Endocrinol. 2025;23:2.","journal-title":"Reprod Biol Endocrinol"},{"key":"2136_CR54","doi-asserted-by":"publisher","first-page":"204201882198923","DOI":"10.1177\/2042018821989238","volume":"12","author":"MA Abdalla","year":"2021","unstructured":"Abdalla MA, Deshmukh H, Atkin S, et al. The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence. Ther Adv Endocrinol Metab. 2021;12:2042018821989238.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2136_CR55","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.17219\/acem\/151695","volume":"31","author":"GS Papaetis","year":"2022","unstructured":"Papaetis GS, Kyriacou A. GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: Current research and future horizons. Adv Clin Exp Med Off Organ Wroclaw Med Univ. 2022;31:1265\u201374.","journal-title":"Adv Clin Exp Med Off Organ Wroclaw Med Univ"},{"key":"2136_CR56","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1016\/j.mayocp.2020.02.019","volume":"95","author":"AM Egan","year":"2020","unstructured":"Egan AM, Dow ML, Vella A. A review of the pathophysiology and management of diabetes in pregnancy. Mayo Clin Proc. 2020;95:2734\u201346.","journal-title":"Mayo Clin Proc"},{"key":"2136_CR57","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ahj.2020.07.008","volume":"229","author":"DH Ryan","year":"2020","unstructured":"Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J. 2020;229:61\u20139.","journal-title":"Am Heart J"},{"key":"2136_CR58","unstructured":"U.S. Department of Health and Human Services. Informed consent. FAQs. (accessed 7 2025). https:\/\/www.hhs.gov\/ohrp\/regulations-and-policy\/guidance\/faq\/informed-consent\/index.html. Accessed 7 2025."},{"key":"2136_CR59","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inf. 2019;95:103208.","journal-title":"J Biomed Inf"},{"key":"2136_CR60","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42:377\u201381.","journal-title":"J Biomed Inf"},{"key":"2136_CR61","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s42255-023-00812-z","volume":"5","author":"R Nogueiras","year":"2023","unstructured":"Nogueiras R, Nauck MA, Tsch\u00f6p MH. Gut hormone co-agonists for the treatment of obesity: from bench to bedside. Nat Metab. 2023;5:933\u201344.","journal-title":"Nat Metab"},{"key":"2136_CR62","doi-asserted-by":"publisher","unstructured":"PoonawallaIB, Bowe A, Tindal M, et al. A real-world comparison of cardiovascular, medical and costs outcomes in new users of SGLT2 inhibitors versus GLP-1 agonists. Diabetes Res Clin Pract. 2021. https:\/\/doi.org\/10.1016\/j.diabres.2021.108800","DOI":"10.1016\/j.diabres.2021.108800"},{"key":"2136_CR63","doi-asserted-by":"publisher","unstructured":"LuoJ, Feldman R, Rothenberger S, et al. 1162-P: Coverage, formulary restrictions, and average retail prices of SGLT2 inhibitors and GLP-1 receptor agonists across Medicare Part D plans in 2019. Diabetes. 2020;69. https:\/\/doi.org\/10.2337\/db20-1162-p","DOI":"10.2337\/db20-1162-p"},{"key":"2136_CR64","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16110","author":"J Wen","year":"2024","unstructured":"Wen J, Razick AA, How-Volkman C, et al. An exploratory analysis of glucagon-like peptide-1 (GLP-1) agonists and biosimilars: A literature review. Diabetes Obes Metab. 2024. https:\/\/doi.org\/10.1111\/dom.16110.","journal-title":"Diabetes Obes Metab"}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-026-02136-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43032-026-02136-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-026-02136-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:04:24Z","timestamp":1785513864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43032-026-02136-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2136"],"URL":"https:\/\/doi.org\/10.1007\/s43032-026-02136-1","relation":{},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"value":"1933-7191","type":"print"},{"value":"1933-7205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approved by the University of Florida IRB. Informed consent to participate was obtained for the anonymous survey.","order":1,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Vlasak, Alexander - Disclosure: none.Palm, Lindsey - Disclosure: none.Minnihan, Alexandra \u2013 Disclosure: none.Rhoton-Vlasak, Alice - Disclosure: none.","order":2,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}